The National Institute for Health and Clinical Excellence (NICE) recommends erlotnib as a first-line treatment for patients afflicted with locally advanced or metastatic non-small-cell lung cancer. NICE notes that erlotnib should, in particular, be prescribed to patients testing positive for mutations to tyrosine kinase (an epidermal growth factor receptor). NICE has studied the effects of erlotnib, both in treatment potential and associated costs. It recommends ernotlib since "it works as well as other treatments available...and costs about the same."
For more information on this guideline, click here.
No comments:
Post a Comment